Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes.

Autor: Garcia-Pelaez J; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Faculty of Medicine, University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal., Barbosa-Matos R; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal., Lobo S; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal., Dias A; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal., Garrido L; Centro Hospitalar Universitário São João, Porto, Portugal., Castedo S; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Faculty of Medicine, University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Centro Hospitalar Universitário São João, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal; European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS), Porto, Portugal., Sousa S; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal., Pinheiro H; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Serviço de Medicina Interna, Centro Hospitalar Tâmega e Sousa, Penafiel, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal., Sousa L; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Escola de Economia e Gestão, Universidade do Minho, Braga, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal., Monteiro R; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal., Maqueda JJ; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Bioinf2Bio, Porto, Portugal., Fernandes S; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal., Carneiro F; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Faculty of Medicine, University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Centro Hospitalar Universitário São João, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal; European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS), Porto, Portugal., Pinto N; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Center of Mathematics, University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal., Lemos C; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal; Institute for Molecular and Cell Biology, University of Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal., Pinto C; Department of Laboratory Genetics, Portuguese Oncology Institute of Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal., Teixeira MR; Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal; Department of Laboratory Genetics, Portuguese Oncology Institute of Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal; European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS), Porto, Portugal., Aretz S; Institute of Human Genetics, Medical Faculty, University of Bonn, Bonn, Germany; National Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany; ERN GENTURIS, Bonn, Germany., Bajalica-Lagercrantz S; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Clinical Genetics, Cancer Genetic Unit, Karolinska University Hospital Solna, Stockholm, Sweden; Cancer Theme, Karolinska University Hospital Solna, Stockholm, Sweden; ERN GENTURIS, Stockholm, Sweden., Balmaña J; Hospital Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; ERN GENTURIS, Barcelona, Spain., Blatnik A; Department of Clinical Cancer Genetics, Institute of Oncology Ljubljana, Ljubljana, Slovenia; ERN GENTURIS, Ljubljana, Slovenia., Benusiglio PR; Medical Genetics Department, Pitié-Salpêtrière Hospital, AP-HP and Sorbonne University, Paris, France., Blanluet M; Service de Génétique Oncologique, Institut Curie, Paris, France., Bours V; Laboratory of Human Genetics, GIGA Institute, University of Liège, Liège, Belgium; Center of Genetics, University Hospital, Liège, Belgium; ERN GENTURIS, Liège, Belgium., Brems H; Department of Human Genetics, University of Leuven, Leuven, Belgium., Brunet J; Hereditary Cancer Programme, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research and Girona Biomedical Research Institute, Barcelona-Girona, Spain; ERN GENTURIS, Barcelona, Spain., Calistri D; Laboratorio di Bioscienze, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Capellá G; Hereditary Cancer Program, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; ERN GENTURIS, Barcelona, Spain., Carrera S; Oncology Service, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, Cruces-Barakaldo, Bizkaia, Spain., Colas C; Service de Génétique Oncologique, Institut Curie, Paris, France; ERN GENTURIS, Paris, France., Dahan K; Center of Human Genetics, IPG, Gosselies, Belgium., de Putter R; Clinical Genetics Department, University Hospital of Ghent, Ghent, Belgium; ERN GENTURIS, Ghent, Belgium., Desseignés C; Medical Genetics Department, Pitié-Salpêtrière Hospital, AP-HP and Sorbonne University, Paris, France., Domínguez-Garrido E; Molecular Diagnostics Laboratory, Fundación Rioja Salud, Logroño, Spain., Egas C; CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal., Evans DG; Division of Evolution and Genomic Sciences, University of Manchester, Manchester, UK; Manchester Centre for Genomic Medicine, Manchester, UK., Feret D; Center of Human Genetics, IPG, Gosselies, Belgium., Fewings E; Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK., Fitzgerald RC; Early Cancer Institute, University of Cambridge, Cambridge, UK., Coulet F; Medical Genetics Department, Pitié-Salpêtrière Hospital, AP-HP and Sorbonne University, Paris, France., Garcia-Barcina M; Genetics Unit, Biocruces Bizkaia Health Research Institute, Basurto University Hospital, Bilbao, Bizkaia, Spain., Genuardi M; Sezione di Medicina Genomica, Dipartimento di Scienze della Vita e Salute Pubblica, Università Cattolica del Sacro Cuore, Rome, Italy; UOC Genetica Medica, Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy; ERN GENTURIS, Rome, Italy., Golmard L; Service de Génétique Oncologique, Institut Curie, Paris, France., Hackmann K; Institute for Clinical Genetics, University Hospital Carl Gustav Carus and Faculty of Medicine, Technische Universität Dresden, Dresden, Germany; National Center for Tumor Diseases, Dresden, Germany: German Cancer Research Center, Heidelberg, Germany; Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany; German Cancer Consortium, Dresden, Germany., Hanson H; SouthWest Thames Regional Genetics Service, St George's University Hospitals NHS Foundation Trust, London, UK., Holinski-Feder E; Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany; Medizinisch Genetisches Zentrum, Munich, Germany; ERN GENTURIS, Munich, Germany., Hüneburg R; Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany; National Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany; ERN GENTURIS, Bonn, Germany., Krajc M; Department of Clinical Cancer Genetics, Institute of Oncology Ljubljana, Ljubljana, Slovenia; ERN GENTURIS, Ljubljana, Slovenia., Lagerstedt-Robinson K; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Clinical Genetics, Cancer Genetic Unit, Karolinska University Hospital Solna, Stockholm, Sweden; ERN GENTURIS, Stockholm, Sweden., Lázaro C; Hereditary Cancer Program, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; ERN GENTURIS, Barcelona, Spain., Ligtenberg MJL; Department of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands; Department of Pathology, Radboud University Medical Center, Nijmegen, Netherlands; Radboud Institute of Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands; ERN GENTURIS, Nijmegen, Netherlands., Martínez-Bouzas C; Genetics Service, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, Cruces-Barakaldo, Bizkaia, Spain., Merino S; Genetics Unit, Biocruces Bizkaia Health Research Institute, Basurto University Hospital, Bilbao, Bizkaia, Spain., Michils G; Department of Human Genetics, University of Leuven, Leuven, Belgium., Novaković S; Department of Molecular Diagnostics, Institute of Oncology Ljubljana, Ljubljana, Slovenia., Patiño-García A; Unidad de Medicina Genómica y Pediatría, Clínica Universidad de Navarra, Programa de Tumores Sólidos, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona, Navarra, Spain., Ranzani GN; Department of Biology and Biotechnology, University of Pavia, Pavia, Italy., Schröck E; Institute for Clinical Genetics, University Hospital Carl Gustav Carus and Faculty of Medicine, Technische Universität Dresden, Dresden, Germany; National Center for Tumor Diseases, Dresden, Germany: German Cancer Research Center, Heidelberg, Germany; Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany; German Cancer Consortium, Dresden, Germany; Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany; ERN GENTURIS, Dresden, Germany., Silva I; GenoMed-Diagnósticos de Medicina Molecular, Lisbon, Portugal., Silveira C; GenoMed-Diagnósticos de Medicina Molecular, Lisbon, Portugal., Soto JL; Molecular Genetics Laboratory, Elche University Hospital, Elche, Spain., Spier I; Institute of Human Genetics, Medical Faculty, University of Bonn, Bonn, Germany; National Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany; ERN GENTURIS, Bonn, Germany., Steinke-Lange V; Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany; Medizinisch Genetisches Zentrum, Munich, Germany; ERN GENTURIS, Munich, Germany., Tedaldi G; Laboratorio di Bioscienze, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Tejada MI; Genetics Service, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, Cruces-Barakaldo, Bizkaia, Spain., Woodward ER; Division of Evolution and Genomic Sciences, University of Manchester, Manchester, UK; Manchester Centre for Genomic Medicine, Manchester, UK., Tischkowitz M; Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK., Hoogerbrugge N; Department of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands; Radboud Institute of Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands; ERN GENTURIS, Nijmegen, Netherlands., Oliveira C; Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal; Faculty of Medicine, University of Porto, Porto, Portugal; Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, Portugal; Porto Comprehensive Cancer Center Raquel Seruca, Porto, Portugal; European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS), Porto, Portugal. Electronic address: carlaol@i3s.up.pt.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2023 Jan; Vol. 24 (1), pp. 91-106. Date of Electronic Publication: 2022 Nov 24.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pancreatic hemi-agenesis in MEN1: A clinical report.

Autor: Vinck WJ; Department of Endocrinology, Sint Augustinus Hospital, Wilrijk, Belgium. Electronic address: wouter.vinck@skynet.be., Van de Mierop F; Department of Gastroenterology, Sint Augustinus Hospital, Wilrijk, Belgium., Van Mieghem F; Department of Radiology, Sint Augustinus Hospital, Wilrijk, Belgium., Vinck M; Department of Biology, KU Leuven, Leuven, Belgium., Becq H; Department of Endocrinology, Sint Augustinus Hospital, Wilrijk, Belgium., Michils G; Centre for Human Genetics, KU Leuven, Leuven, Belgium.

Publikováno v: European journal of medical genetics [Eur J Med Genet] 2018 Apr; Vol. 61 (4), pp. 181-184. Date of Electronic Publication: 2017 Nov 23.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy.

Autor: Chehelgerdi, Mohammad^1,2 (AUTHOR) Chehelgerdi1992@gmail.com, Chehelgerdi, Matin^1,2 (AUTHOR), Khorramian-Ghahfarokhi, Milad³ (AUTHOR), Shafieizadeh, Marjan⁴ (AUTHOR), Mahmoudi, Esmaeil² (AUTHOR), Eskandari, Fatemeh⁵ (AUTHOR), Rashidi, Mohsen^6,7 (AUTHOR), Arshi, Asghar⁸ (AUTHOR), Mokhtari-Farsani, Abbas^1,9 (AUTHOR)

Publikováno v: Molecular Cancer. 1/9/2024, Vol. 23 Issue 1, p1-45. 45p.